Condition

HIV Pre-Exposure Prophylaxis

ClinicalTrials.gov condition label

Clinical trials6

Recruiting2

Common interventions13

Lead sponsors shown3

Clinical trials

6 shown

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)NCT07071623 · 2025-11-10

Vienna HIV Infection Via Sex StudyNCT05326061 · 2020-07-01

A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)NCT07600775 · 2026-09-01

NOT_YET_RECRUITING

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)NCT07044297 · 2025-07-31

ACTIVE_NOT_RECRUITING

Supporting Tailored And Responsive PrEP in Rural North CarolinaNCT05984030 · 2023-08-31

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)NCT06783192 · 2023-08-14

Common interventions

MK-8527DRUG4 Emtricitabine/tenofovir disoproxil (FTC/TDF)DRUG1 FTC/TDFDRUG1 HealthMpowerment Digital Health Intervention - BasicBEHAVIORAL1 HealthMpowerment Digital Health Intervention - EnhancedBEHAVIORAL1 LNG/EEDRUG1 Placebo matched to FTC/TDFDRUG1 Placebo matched to MK-8527DRUG1 Placebo to FTC/TDFDRUG1 Placebo to MK-8527DRUG1 PrEP Navigation ServicesOTHER1 RifampinDRUG1 Telehealth PrEP Services ReferralOTHER1

Leading sponsors

Merck Sharp & Dohme LLC4 Medical University of Vienna1 University of North Carolina, Chapel Hill1

Trial status mix

COMPLETED2

RECRUITING2

ACTIVE_NOT_RECRUITING1

NOT_YET_RECRUITING1

Phase mix

PHASE12

PHASE32

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.